CN110464815A - 一种新型姜黄复合固体制剂及其制备方法 - Google Patents
一种新型姜黄复合固体制剂及其制备方法 Download PDFInfo
- Publication number
- CN110464815A CN110464815A CN201910560459.XA CN201910560459A CN110464815A CN 110464815 A CN110464815 A CN 110464815A CN 201910560459 A CN201910560459 A CN 201910560459A CN 110464815 A CN110464815 A CN 110464815A
- Authority
- CN
- China
- Prior art keywords
- turmeric
- curcumin
- added
- solid preparation
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000003392 Curcuma domestica Nutrition 0.000 title claims abstract description 171
- 235000003373 curcuma longa Nutrition 0.000 title claims abstract description 171
- 235000013976 turmeric Nutrition 0.000 title claims abstract description 171
- 238000002360 preparation method Methods 0.000 title claims abstract description 35
- 239000007787 solid Substances 0.000 title claims abstract description 33
- 244000008991 Curcuma longa Species 0.000 title abstract 11
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims abstract description 184
- 244000163122 Curcuma domestica Species 0.000 claims abstract description 160
- 235000012754 curcumin Nutrition 0.000 claims abstract description 93
- 229940109262 curcumin Drugs 0.000 claims abstract description 92
- 239000004148 curcumin Substances 0.000 claims abstract description 92
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims abstract description 92
- 239000000835 fiber Substances 0.000 claims abstract description 40
- 239000000341 volatile oil Substances 0.000 claims abstract description 33
- 239000000945 filler Substances 0.000 claims abstract description 28
- 230000001804 emulsifying effect Effects 0.000 claims abstract description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 26
- 235000013305 food Nutrition 0.000 claims abstract description 21
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 12
- 239000000843 powder Substances 0.000 claims description 35
- 239000007788 liquid Substances 0.000 claims description 33
- 238000010438 heat treatment Methods 0.000 claims description 26
- 238000001914 filtration Methods 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- 239000008367 deionised water Substances 0.000 claims description 18
- 229910021641 deionized water Inorganic materials 0.000 claims description 18
- 239000000706 filtrate Substances 0.000 claims description 18
- 239000002893 slag Substances 0.000 claims description 18
- 238000000605 extraction Methods 0.000 claims description 17
- 239000000463 material Substances 0.000 claims description 17
- 239000012141 concentrate Substances 0.000 claims description 16
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- 229920000223 polyglycerol Polymers 0.000 claims description 8
- 229920000881 Modified starch Polymers 0.000 claims description 7
- 239000004368 Modified starch Substances 0.000 claims description 7
- 235000019426 modified starch Nutrition 0.000 claims description 7
- 229920002774 Maltodextrin Polymers 0.000 claims description 6
- 239000005913 Maltodextrin Substances 0.000 claims description 6
- 229940035034 maltodextrin Drugs 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 2
- 238000005507 spraying Methods 0.000 claims description 2
- 229920002261 Corn starch Polymers 0.000 claims 1
- 229920001503 Glucan Polymers 0.000 claims 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims 1
- 108010073771 Soybean Proteins Proteins 0.000 claims 1
- 108010046377 Whey Proteins Proteins 0.000 claims 1
- 102000007544 Whey Proteins Human genes 0.000 claims 1
- 239000008120 corn starch Substances 0.000 claims 1
- 229940099112 cornstarch Drugs 0.000 claims 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims 1
- 235000019710 soybean protein Nutrition 0.000 claims 1
- 235000021119 whey protein Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 9
- 238000005516 engineering process Methods 0.000 abstract description 8
- 239000002994 raw material Substances 0.000 abstract description 3
- 230000035622 drinking Effects 0.000 abstract description 2
- 235000008216 herbs Nutrition 0.000 abstract description 2
- 230000010354 integration Effects 0.000 abstract description 2
- 235000015097 nutrients Nutrition 0.000 abstract description 2
- 238000001035 drying Methods 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 239000006210 lotion Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 60
- 239000000284 extract Substances 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- KKAJSJJFBSOMGS-UHFFFAOYSA-N 3,6-diamino-10-methylacridinium chloride Chemical compound [Cl-].C1=C(N)C=C2[N+](C)=C(C=C(N)C=C3)C3=CC2=C1 KKAJSJJFBSOMGS-UHFFFAOYSA-N 0.000 description 7
- 241000234314 Zingiber Species 0.000 description 7
- 235000006886 Zingiber officinale Nutrition 0.000 description 7
- 239000001913 cellulose Substances 0.000 description 7
- 229920002678 cellulose Polymers 0.000 description 7
- 238000004821 distillation Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 235000008397 ginger Nutrition 0.000 description 7
- 235000005979 Citrus limon Nutrition 0.000 description 6
- 244000131522 Citrus pyriformis Species 0.000 description 6
- 239000012981 Hank's balanced salt solution Substances 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 244000068988 Glycine max Species 0.000 description 4
- 235000010469 Glycine max Nutrition 0.000 description 4
- 239000013553 cell monolayer Substances 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 238000004945 emulsification Methods 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 239000013558 reference substance Substances 0.000 description 3
- 239000007962 solid dispersion Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 238000001256 steam distillation Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000006937 anti-inflammatory bioactivity Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 150000002576 ketones Chemical group 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- -1 polyethylene pyrrole Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/40—Shaping or working of foodstuffs characterised by the products free-flowing powder or instant powder, i.e. powder which is reconstituted rapidly when liquid is added
- A23P10/47—Shaping or working of foodstuffs characterised by the products free-flowing powder or instant powder, i.e. powder which is reconstituted rapidly when liquid is added using additives, e.g. emulsifiers, wetting agents or dust-binding agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明涉及一种以药食同源资源姜黄提取物姜黄素、姜黄挥发油、姜黄可溶纤维为原料,制备姜黄复合固体制剂,本发明的姜黄复合固体制剂由以下组分重量百分比组成:姜黄素0.5%~30%,姜黄可溶纤维0.5%~50%,姜黄挥发油1%~10%,食品乳化剂0.5%~10%,填充剂余量。本发明技术充分提取并应用了姜黄的有效成分姜黄素、姜黄挥发油及姜黄可溶纤维,通过乳液均质乳化、浓缩及干燥工艺,得到姜黄复合固体制剂,有效地改善姜黄素的水溶性和生物利用度,可作为功能原料应用于食品、营养保健品、医药等领域。
Description
技术领域
本发明属于食品、营养保健品、医药等技术领域。本发明涉及一种姜黄复合固体制剂及其制备方法,特别涉及一种以姜黄素、姜黄可溶纤维、姜黄挥发油、食品乳化剂、填充剂为原辅料制备成的姜黄复合固体制剂及其制备方法。
背景技术
姜黄来源于药食同源姜科植物姜黄的干燥根茎,性味辛、苦、温,归脾、肝经。姜黄的功效为破血行气、通经止痛,用于胸胁刺痛、胸痹心痛、痛经、经闭、症瘕、风湿、肩臂疼痛、跌扑肿痛。姜黄的活性成分主要有姜黄素、挥发油、多糖等。姜黄素(curcumin)物界具有二酮结构的天然酚类色素,呈橙黄色,具有良好的清除自由基、抗氧化、抗炎、骨关节炎、延缓老年痴呆等功效。姜黄素常用于食品和化妆品作为天然的抗氧化剂、天然色素及食品咖喱调味剂,大量临床研究结果证实食用姜黄素的安全性很高,几乎没有毒性。然而姜黄素在水中溶解度低,体内吸收差,对光、热、酸碱条件较为敏感,容易分解失效,导致姜黄素无法在营养保健食品、医药领域得到有效应用,国内仅将姜黄与姜黄素作为色素食品添加剂(见GB2760),基于此,改善姜黄素的水溶性、稳定性及生物利用度非常重要。关于姜黄素溶解性和稳定性的研究较多,其中专利CN108815123A、CN109045064采用聚乙烯吡络烷酮、泊洛沙姆等非普通食品可用增溶剂制备姜黄素固体分散体。同时国内外也采用环糊精、聚乳酸等高分子材料,应用纳米包埋、固体分散、包合技术、反胶束体系及改性等技术进行增溶研究,主要存在所使用的增溶剂未被列入GB2760允许使用或其允许添加量太小,难以改善姜黄素水溶性,不符合我国食品相关法律法规的要求。
此外,姜黄中还含有姜黄挥发油及姜黄可溶纤维(以姜黄多糖为主),具有抗炎、抗氧化等多种生物活性。目前国内外以采用高分子材料改善姜黄素水溶性与稳定性为主:专利CN108815123A采用聚乙烯吡咯烷酮、泊洛沙姆188等为辅料制备姜黄素固体分散体,专利CN107496359A采用Pluronic F127等为辅料制备姜黄素脂质体,专利CN106943604A采用环糊精聚合物制备水溶性姜黄素超分子包合物,暂未见关于采用姜黄自身可溶纤维吸附分散姜黄素的相关文献、专利报道。本发明采用姜黄可溶纤维、食品乳化剂对姜黄素进行包裹,达到姜黄素的协同增溶作用,提高姜黄素的水溶性和生物利用度。
发明内容
本发明目的在于提供一种新型姜黄复合固体制剂及其制备方法。
鉴于上述和/或现有水溶性姜黄素应用过程中存在的问题,提出了本发明技术。
因此,为解决上述技术的问题,本发明提供如下技术方案:从姜黄药材中提取姜黄挥发油、姜黄素、姜黄可溶纤维,采用食品乳化剂、姜黄可溶纤维作为壁材。首先取姜黄药材经水蒸气蒸馏法制备姜黄挥发油,其次在提取姜黄素过程中加入乳化剂,得到均匀姜黄素乳化溶液,再制备姜黄可溶纤维填充剂溶液,将以两种溶液进一步乳化混合,经减压浓缩与喷雾干燥得到姜黄素提取物,将姜黄素提取物与姜黄挥发油按配方混合,即得新型姜黄复合固体制剂。
一种具抗炎症功能的姜黄复合固体制剂,其特征在于,所述的姜黄复合固体制剂由以下组分百分比组成:姜黄素0.5%~30%,姜黄可溶纤维0.5%~50%,姜黄挥发油1%~10%,食品乳化剂0.5%~10%,填充剂余量。
本发明提供的一种具抗炎症功能的姜黄复合固体制剂,通过以下步骤制备:
(1)取姜黄药材,粉碎并过24目筛,得到姜黄药粉;
(2)取姜黄药粉,按料液比1:4~1:15加入去离子水,浸润15~25 min,在100℃加热蒸馏提取4~10 h,经分离萃取收集,得到姜黄挥发油;
(3)将步骤(2)提取后的姜黄药粉渣,按料液比1:5~1:12加入60-95%乙醇水,在50~65℃加热提取2~5 h,提取2次,100目过滤,合并滤液得到姜黄素乙醇溶液,按配方量加入食品乳化剂,于3000 rpm均质乳化,得到姜黄素乳化溶液;
(4)将步骤(3)提取后的姜黄药粉渣,按料液比1:5~1:10加入去离子水,用柠檬酸调节pH到5.0-6.5,在80-100℃加热12~36 h,100目过滤,合并滤液,按配方量加入填充剂,于3000 rpm均质乳化,得到姜黄可溶纤维填充剂溶液;
(5)将姜黄素乳化溶液与姜黄可溶纤维填充剂溶液混合,于3000 rpm均质乳化1~3 h后,在45~65℃条件下进行减压浓缩,得到浓缩液;
(6)将步骤(5)所得浓缩液在进风温度为165~180℃,出风温度为80~90℃进行喷雾干燥,即得姜黄素提取物;
(7)将姜黄素提取物、姜黄挥发油按配方量混合,搅拌均匀,即得姜黄复合固体制剂。
优选的,所述食品乳化剂为吐温-20、聚甘油单油酸酯。
优选的,所述填充剂包括食用级的麦芽糊精、改性淀粉。
优选的,所述姜黄挥发油提取料液比为1:8~1:10。
优选的,所述姜黄素提取料液比为1:10~1:12。
优选的,所述姜黄素提取加入乙醇水溶液浓度为70%。
优选的,所述姜黄可溶纤维提取料液比为1:8~1:10。
优选的,所述取姜黄药粉,按料液比1:10加入去离子水,浸润25 min,在100℃加热蒸馏提取6 h,经分离萃取收集,得到姜黄挥发油。
优选的,所述提取后的姜黄药粉渣,按料液比1:10加入70%乙醇水,在65℃加热提取2 h,提取2次,100目过滤,合并滤液得到姜黄素乙醇溶液,按配方量加入食品乳化剂,于3000 rpm均质乳化,得到姜黄素乳化溶液。
优选的,所述提取姜黄素后的姜黄药粉渣,按料液比1:8加入去离子水,用柠檬酸调节pH到6.0,在100℃加热24 h,100目过滤,并合并滤液,得到姜黄可溶纤维溶液,按配方量加入填充剂,于3000 rpm均质乳化,得到姜黄可溶纤维填充剂溶液。
本发明的有益效果:
(1)本发明创新地采用姜黄可溶纤维与食品上允许使用的乳化剂对姜黄素进行乳化增溶,首先取姜黄药材经水蒸气蒸馏法制备姜黄挥发油,其次在提取姜黄素过程中加入乳化剂,得到均匀姜黄素乳化溶液,再制备姜黄可溶纤维填充剂溶液,将以两种溶液进一步乳化混合,经减压浓缩与喷雾干燥得到姜黄素提取物,将姜黄素提取物与姜黄挥发油按配方混合,即得姜黄复合固体制剂,在提高姜黄素水溶性的基础上,增加了配方协同抗炎的生物活性,所用原料符合我国食品法规,制备工艺绿色环保,可进行产业化推广应用。
(2)本发明技术在姜黄药材提取过程中直接乳化包埋,制备以姜黄挥发油、姜黄素与姜黄可溶纤维为主成分的姜黄,充分利用姜黄活性成分,降低生产成本,适合产业化推广应用。
(3)本发明采用的姜黄挥发油具有良好的抗炎生物活性,在配方中与姜黄提取物协同增效,进一步提高姜黄素的生物活性。
具体实施方式
以下结合具体实施例对本发明进行进一步说明。
下面通过实施例进一步描述本发明,但本发明并不仅限于所述实施例。
实施例1
(1)取姜黄药材,粉碎并过24目筛,得到姜黄药粉;
(2)取姜黄药粉,按料液比1:8加入去离子水,浸润20 min,在100℃加热蒸馏提取6 h,经分离萃取收集,得到姜黄挥发油;
(3)将步骤(2)提取后的姜黄药粉渣,按料液比1:10加入65%乙醇水,在65℃加热提取2h,提取2次,100目过滤,合并滤液得到姜黄素乙醇溶液,加入5%聚甘油单油酸酯,于3000rpm均质乳化,得到姜黄素乳化溶液;
(4)将步骤(3)提取后的姜黄药粉渣,按料液比1:10加入去离子水,用柠檬酸调节pH到5.0,在100℃加热36 h,100目过滤,合并滤液得到姜黄可溶纤维溶液,加入50%麦芽糊精与10%变性淀粉,与3000 rpm均质乳化,得到姜黄可溶纤维填充剂溶液;
(5)将姜黄素乳化溶液、姜黄可溶纤维填充剂溶液混合,于3000 rpm均质乳化1 h后,在45℃条件下进行减压浓缩,得到浓缩液;
(6)将步骤(5)所得浓缩液在进风温度为165℃,出风温度为80℃进行喷雾干燥,即得姜黄素提取物;
(7)按配方中姜黄素含量为20%与5%姜黄挥发油混合,搅拌均匀,即得姜黄复合固体制剂。
实施例2
(1)取姜黄药材,粉碎并过24目筛,得到姜黄药粉,备用;
(2)取姜黄药粉,按料液比1:10加入去离子水,浸润25 min,在100℃加热蒸馏提取6 h,经分离萃取收集,得到姜黄挥发油;
(3)将步骤(2)提取后的姜黄药粉渣,按料液比1:8加入80%乙醇水,在65℃加热提取3h,提取2次,100目过滤,合并滤液得到姜黄素乙醇溶液,加入2%聚甘油单油酸酯与3%吐温-20,于3000 rpm均质乳化,得到姜黄素乳化溶液;
(4)将步骤(3)提取后的姜黄药粉渣,按料液比1:5加入去离子水,用柠檬酸调节pH到5.5,在100℃加热12 h,100目过滤,合并滤液得到姜黄可溶纤维溶液,加入50%改性淀粉,于3000 rpm均质乳化,得到姜黄可溶纤维填充剂溶液;
(5)将姜黄素乳化溶液、姜黄可溶纤维填充剂溶液混合,于3000 rpm均质乳化3 h后,在65℃条件下进行减压浓缩,得到浓缩液;
(6)将步骤(5)所得浓缩液在进风温度为180℃,出风温度为80℃进行喷雾干燥,即得姜黄素提取物;
(7)按配方中姜黄素含量为10%与8%姜黄挥发油,混合搅拌均匀,即得姜黄复合固体制剂。
实施例3
(1)取姜黄药材,粉碎并过24目筛,得到姜黄药粉,备用;
(2)取姜黄药粉,按料液比1:6加入去离子水,浸润20 min,在100℃加热蒸馏提取4 h,经分离萃取收集,得到姜黄挥发油;
(3)将步骤(2)提取后的姜黄药粉渣,按料液比1:8加入70%乙醇水,在60℃加热提取4h,提取2次,100目过滤,合并滤液得到姜黄素乙醇溶液,加入4%聚甘油单油酸酯与1%大豆分离蛋白,于3000 rpm均质乳化,得到姜黄素乳化溶液;
(4)将步骤(3)提取后的姜黄药粉渣,按料液比1:7加入去离子水,用柠檬酸调节pH到6.5,在100℃加热18 h,100目过滤,合并滤液得到姜黄可溶纤维溶液,加入50%改性淀粉,于3000 rpm均质乳化,得到姜黄可溶纤维填充剂溶液;
(5)将姜黄素乳化溶液、姜黄可溶纤维填充剂溶液混合,于3000 rpm均质乳化3 h后,在55℃条件下进行减压浓缩,得到浓缩液;
(6)将步骤(5)所得浓缩液在进风温度为175℃,出风温度为85℃进行喷雾干燥,即得姜黄素提取物;
(7)按配方中姜黄素含量为30%与10%姜黄挥发油,混合搅拌均匀,即得姜黄复合固体制剂。
实施例4
(1)取姜黄药材,粉碎并过24目筛,得到姜黄药粉,备用;
(2)取姜黄药粉,按料液比1:15加入去离子水,浸润20 min,在100℃加热蒸馏提取5 h,经分离萃取收集,得到姜黄挥发油;
(3)将步骤(2)提取后的姜黄药粉渣,按料液比1:12加入70%乙醇水,在60℃加热提取5h,提取2次,100目过滤,合并滤液得到姜黄素乙醇溶液,加入3%聚甘油单油酸酯与2%大豆分离蛋白,于3000 rpm均质乳化,得到姜黄素乳化溶液;
(4)将步骤(3)提取后的姜黄药粉渣,按料液比1:8加入去离子水,用柠檬酸调节pH到6.0,在80℃加热20 h,100目过滤,合并滤液得到姜黄可溶纤维溶液,加入30%改性淀粉及20%麦芽糊精,于3000 rpm均质乳化,得到姜黄可溶纤维填充剂溶液;
(5)将姜黄素乳化溶液、姜黄可溶纤维填充剂溶液混合,于3000 rpm均质乳化1.5 h后,在60℃条件下进行减压浓缩,得到浓缩液;
(6)将步骤(5)所得浓缩液在进风温度为175℃,出风温度为85℃进行喷雾干燥,即得姜黄素提取物;
(7)按配方中姜黄素含量为15%与16%姜黄挥发油,混合搅拌均匀,即得姜黄复合固体制剂。
实施例5
(1)取姜黄药材,粉碎并过24目筛,得到姜黄药粉,备用;
(2)取姜黄药粉,按料液比1:12加入去离子水,浸润20 min,在100℃加热蒸馏提取8 h,经分离萃取收集,得到姜黄挥发油;
(3)将步骤(2)提取后的姜黄药粉渣,按料液比1:9加入85%乙醇水,在55℃加热提取3h,提取2次,100目过滤,合并滤液得到姜黄素乙醇溶液,加入3%聚甘油单油酸酯与2%大豆分离蛋白,于3000 rpm均质乳化,得到姜黄素乳化溶液;
(4)将步骤(3)提取后的姜黄药粉渣,按料液比1:9加入去离子水,用柠檬酸调节pH到5.8,在92℃加热14 h,100目过滤,合并滤液得到姜黄可溶纤维溶液,加入25%改性淀粉及25%麦芽糊精,于3000 rpm均质乳化,得到姜黄可溶纤维填充剂溶液;
(5)将姜黄素乳化溶液、姜黄可溶纤维填充剂溶液混合,于3000 rpm均质乳化1.5 h后,在60℃条件下进行减压浓缩,得到浓缩液;
(6)将步骤(5)所得浓缩液在进风温度为175℃,出风温度为85℃进行喷雾干燥,即得姜黄素提取物;
(7)按配方中姜黄素含量为20%与3%姜黄挥发油,混合搅拌均匀,即得姜黄复合固体制剂。
实施例6
(1)取姜黄药材,粉碎并过24目筛,得到姜黄药粉,备用;
(2)取姜黄药粉,按料液比1:7加入去离子水,浸润20 min,在100℃加热蒸馏提取6.5h,经分离萃取收集,得到姜黄挥发油;
(3)将步骤(2)提取后的姜黄药粉渣,按料液比1:7加入90%乙醇水,在55℃加热提取2h,提取2次,100目过滤,合并滤液得到姜黄素乙醇溶液,加入4%聚甘油单油酸酯与1%大豆分离蛋白,于3000 rpm均质乳化,得到姜黄素乳化溶液;
(4)将步骤(3)提取后的姜黄药粉渣,按料液比1:8.5加入去离子水,用柠檬酸调节pH到5.0,在100℃加热25h,100目过滤,合并滤液得到姜黄可溶纤维溶液,加入25%改性淀粉及25%麦芽糊精,于3000 rpm均质乳化,得到姜黄可溶纤维填充剂溶液;
(5)将姜黄素乳化溶液、姜黄可溶纤维填充剂溶液混合,于3000 rpm均质乳化2 h后,在60℃条件下进行减压浓缩,得到浓缩液;
(6)将步骤(5)所得浓缩液在进风温度为175℃,出风温度为85℃进行喷雾干燥,即得姜黄素提取物;
(7)按配方中姜黄素含量为10%与1%姜黄挥发油,混合搅拌均匀,即得姜黄复合固体制剂。
实施例7
实验1 姜黄复合固体制剂溶解度测定
1.1 实验方法
1.1.1 色谱条件
Lunar C18色谱柱(150 mm × 4.6 mm,5 μm);流动相为甲醇-5%冰醋酸(70:30);流速为1.0 mL/rnin检测波长为425 nm(根据最大吸收波长确定);进样量为10 μL。确定姜黄素吸收峰保留时间。理论塔板数按姜黄素峰计,应不低于5000。
1.1.2 标准曲线
准确称取姜黄素对照品2.05 mg,加甲醇溶解定容至10.0 mL,配成质量浓度为205 μg/mL的贮备液。将对照品溶液分别稀释成(1)低浓度0.33、0.66、0.99、1.33、1.66、1.99 μg/mL;(2)高浓度8.28、16.57、24.85、33.14、44.12 μg/mL依法测定,记录峰面积,以药物浓度C对峰面积A进行线性回归。
1.1.3 样品处理
取过量95%含量姜黄素、市售水溶性姜黄素(15%)及实施例1~6中姜黄复合固体制剂溶于10 mL去离子水中,置于常温条件下的摇床中以一定转速摇匀溶解24 h,取姜黄素水溶液离心,取上清液按1.1.1与1.1.2条件进样,测定并计算姜黄素含量。
1.2 实验结果
样品溶解度实验结果见表1所示,由结果可知,姜黄复合固体制剂溶解度最高,明显优于市售水溶性姜黄素样品,提示本发明技术之优势。
表1 姜黄素溶解度结果
样品 | 浓度(μg/mL) | 含量(μg/mL) |
95%姜黄素 | 0.0011 | 0.26 |
市售水溶性姜黄素(15%) | 0.0105 | 2.52 |
实施例1 | 0.0385 | 9.24 |
实施例2 | 0.0926 | 22.22 |
实施例3 | 0.0442 | 10.61 |
实施例4 | 0.0579 | 13.90 |
实施例5 | 0.0638 | 15.31 |
实施例6 | 0.0776 | 18.62 |
实验2 姜黄复合固体制剂体外吸收实验
2.1 实验方法
2.1.1 色谱条件
采用高效液相紫外色谱法检测姜黄素的含量,条件如下:色谱柱,DIKMA C18 反相色谱柱(ID 4.6 mm×150 mm,5 µm);流动相,乙腈-0.2%醋酸(27.5:72.5);流速,1.0 mL/min;检测波长,290 nm;柱温,40℃;进样量,10 µL。
2.1.2 标准曲线
精密称取姜黄素对照品适量置于100 mL量瓶中,加甲醇适量溶解、摇匀、滤过,制成约10 μg/mL的溶液,作为供试品溶液。用空白HBSS稀释成一系列溶液,过滤,依法测定,记录峰面积。以药物浓度C对峰面积A进行线性回归。得标准曲线方程y=1.516x+0.00331,R2=0.9992。结果表明,在0.01351 μg/mL至0.457848 μg/mL范围内成良好的线性关系。
2.1.3 样品处理
取符合转运实验的Transwell板,于实验前缓慢吸弃旧培养液,加入37℃预热的HBSS荡洗细胞三次,最后一次置于37℃培养箱温孵30 min后,缓慢吸弃HBSS溶液,洗去细胞单分子层表面的杂质并以期不破坏其细胞单层膜,而后用不同的样品处理开展药物转运实验。用pH 6.5 HBSS(含10 mM methanesulfonic acid,pH 6.5)溶液配制姜黄素或者固体制剂溶液(相当于20 μg/mL姜黄素),经过滤除菌,用空白pH 7.4 HBSS溶液冲洗Transwell板3遍,最后一次放培养箱中培养30 min。对于从Apical(肠腔侧)到Basolateral(基底侧)转运:将0.4 mL药物溶液加到Apical作为供给池,同时Basolateral侧加入1.2 mL空白pH 7.4 HBSS溶液(含25 mM HEPES + 4% BSA,pH 7.4)作为接收池;将板置于37℃中100 rpm振摇,分别在0、15、30、45、60、90和120 min不同时间吸取600 µL接收液,及时补液。将所取样品与丙酮1:2涡旋混合,12000 rpm离心15 min。上清液过滤(0.45)μm后在HPLC上分析。
2.1.4 实验评价
通过测定姜黄素通过细胞单层的浓度,计算姜黄素透过Caco-2细胞单层的表观渗透系数(Apparent permeability coefficient,P app,cm·sec-1)进行数据处理。Papp值越大,通透率越高。表观渗透系数根据药物在不同时间内转运通过小肠囊或Caco-2细胞BL侧的药量对时间回归得到直线斜率。按照下式计算表现渗透系数P app。
P app=(dQ / dt) / (A x C0)
式中:dQ/dt为渗透速率(µmol/s),即在dt时间段内透过的药量;A为细胞单层表面积(cm2)即膜面积,本实验中A为1.12 cm2;C0为给药侧的药物的初始浓度(µg/mL)。
2.1.5 实验结果
由结果可知,吸收率大小顺序分别为姜黄复合固体制剂>市售水溶性姜黄素>95%姜黄素,进一步说明本发明技术制备的姜黄复合固体制剂能有效促进姜黄素的吸收率。也进一步体现本发明技术之优势。
表2 各组样品吸收率
样品 | 吸收率(%) |
95%姜黄素 | 30.25 |
市售水溶性姜黄素(15%) | 60.08 |
实施例1 | 75.94 |
实施例2 | 88.33 |
实施例3 | 69.47 |
实施例4 | 80.51 |
实施例5 | 73.08 |
实施例6 | 83.19 |
以上所述,仅为本发明的较佳的具体实施例,但本发明的保护范围并不局限于此,任何熟悉本技术领域的技术人员在本发明揭露的技术范围内,根据本发明的技术方案及其构思加以等同替换或改变,都应涵盖在本发明的保护范围内。
Claims (4)
1.一种新型姜黄复合固体制剂,其特征在于,所述的新型姜黄复合固体制剂由以下组分百分比组成:姜黄素0.5%~30%,姜黄可溶纤维0.5%~50%,姜黄挥发油1%~10%,食品乳化剂0.5%~10%,填充剂余量。
2.根据权利要求1所述的一种新型姜黄复合固体制剂,其特征在于所述的食品乳化剂包括乳清分离蛋白、大豆分离蛋白、吐温-20、聚甘油单油酸酯、PEG-400食品乳化剂中的一种或多种混合物。
3.根据权利要求1所述的一种新型姜黄复合固体制剂,其特征在于所述的填充剂包括食用级的葡聚糖、水溶性玉米淀粉、低聚异麦芽糖、低聚木糖、麦芽糊精、改性淀粉中的一种或多种混合物。
4.根据权利要求1所述的一种新型姜黄复合固体制剂的制备方法,其特征在于通过下述步骤制备得到:
(1)取姜黄药材,粉碎并过24目筛,得到姜黄药粉;
(2)取姜黄药粉,按料液比1:4~1:15加入去离子水,浸润15~25 min,在100℃加热蒸馏提取4~10 h,经分离萃取收集,得到姜黄挥发油;
(3)将步骤(2)提取后的姜黄药粉渣,按料液比1:5~1:12加入60-95%乙醇水,在50~65℃加热提取2~5 h,提取2次,100目过滤,合并滤液得到姜黄素乙醇溶液,按配方量加入食品乳化剂,于3000 rpm进行均质乳化,得到姜黄素乳化溶液;
(4)将步骤(3)提取后的姜黄药粉渣,按料液比1:5~1:10加入去离子水,用柠檬酸调节pH到5.0-6.5,在80-100℃加热12~36 h,100目过滤,合并滤液,按配方量加入填充剂,于3000 rpm均质乳化,得到姜黄可溶纤维填充剂溶液;
(5)将姜黄素乳化溶液与姜黄可溶纤维填充剂溶液混合,于3000 rpm均质乳化1~3 h后,在45~65℃条件下进行减压浓缩,得到浓缩液;
(6)将步骤(5)所得浓缩液在进风温度为165~180℃,出风温度为80~90℃进行喷雾干燥,即得姜黄素提取物;
(7)将姜黄素提取物、姜黄挥发油按配方量混合,搅拌均匀,即得姜黄复合固体制剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910560459.XA CN110464815A (zh) | 2019-06-26 | 2019-06-26 | 一种新型姜黄复合固体制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910560459.XA CN110464815A (zh) | 2019-06-26 | 2019-06-26 | 一种新型姜黄复合固体制剂及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110464815A true CN110464815A (zh) | 2019-11-19 |
Family
ID=68507453
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910560459.XA Pending CN110464815A (zh) | 2019-06-26 | 2019-06-26 | 一种新型姜黄复合固体制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110464815A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112716896A (zh) * | 2020-09-21 | 2021-04-30 | 完美(中国)有限公司 | 一种姜黄全提物纳米乳固体制剂及其制备方法 |
CN114568615A (zh) * | 2022-03-30 | 2022-06-03 | 闽江学院 | 一种功能性复合速溶粉及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140010903A1 (en) * | 2012-07-04 | 2014-01-09 | Akay Flavours & Aromatics Pvt Ltd. | Curcuminoid composition with enhanced bioavailability and a process for its preparation |
US20160151440A1 (en) * | 2013-08-19 | 2016-06-02 | Aurea Biolabs Private Limited | A Novel Composition of Curcumin with Enhanced Bioavailability |
WO2018083677A1 (en) * | 2016-11-07 | 2018-05-11 | Akay Flavours & Aromatics Pvt. Ltd. | Green approach in enhancing the bioavailability of oils, fats and other lipophilic bioactives and compositions thereof |
-
2019
- 2019-06-26 CN CN201910560459.XA patent/CN110464815A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140010903A1 (en) * | 2012-07-04 | 2014-01-09 | Akay Flavours & Aromatics Pvt Ltd. | Curcuminoid composition with enhanced bioavailability and a process for its preparation |
US20160151440A1 (en) * | 2013-08-19 | 2016-06-02 | Aurea Biolabs Private Limited | A Novel Composition of Curcumin with Enhanced Bioavailability |
WO2018083677A1 (en) * | 2016-11-07 | 2018-05-11 | Akay Flavours & Aromatics Pvt. Ltd. | Green approach in enhancing the bioavailability of oils, fats and other lipophilic bioactives and compositions thereof |
Non-Patent Citations (1)
Title |
---|
刘芳;张倩;李锐;肖洪涛;邝婷婷;欧阳雪倩;殷恒福;: "表面活性剂对姜黄素类成分水溶性与抗肝纤维化作用的影响" * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112716896A (zh) * | 2020-09-21 | 2021-04-30 | 完美(中国)有限公司 | 一种姜黄全提物纳米乳固体制剂及其制备方法 |
CN114568615A (zh) * | 2022-03-30 | 2022-06-03 | 闽江学院 | 一种功能性复合速溶粉及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101062077B (zh) | 一种同时制备甜叶菊总甜菊苷和甜叶菊总黄酮的方法 | |
CN103702675B (zh) | 具有增加含量的活性类黄酮化合物的漆树提取物及其制备方法 | |
US20150174188A1 (en) | Methods for inhibiting advanced glycation end product production, inhibiting fibroblast apoptosis, and/or promoting human fibroblast-collagen grating formulation using cherry blossom and cherry leaf extract | |
CN105411951B (zh) | 黑柄炭角菌提取物在美白保湿化妆品中的应用 | |
CN110464815A (zh) | 一种新型姜黄复合固体制剂及其制备方法 | |
KR101734896B1 (ko) | 감나무 추출물을 유효성분으로 포함하는 각막 손상의 예방, 개선 또는 치료용 조성물 | |
CN1698620B (zh) | 一种可过滤除菌的葫芦素乳剂及制备方法 | |
TWI465237B (zh) | 神經芽細胞增殖促進劑及神經突起伸展劑 | |
KR101692032B1 (ko) | 얼레지 추출물을 포함하는 항암 조성물 | |
US20200061146A1 (en) | Method for preparing curcuma xanthorrhiza roxb. extract | |
CN105519734A (zh) | 一种金银花山绿茶代用茶及其制备方法 | |
KR102137136B1 (ko) | 호박 가수분해 추출물, 구약감자 가수분해 추출물, 강황 추출물 및 카카오닙스 추출물을 포함하는 조성물 | |
CN104337731A (zh) | 神经酰胺和/或葡萄糖神经酰胺产生促进剂或者保湿剂 | |
CN107496775B (zh) | 壮药组合物的提取工艺及应用 | |
KR102115669B1 (ko) | 벤조피렌의 생성은 억제되면서 사포닌은 증진되고 플라티코딘 d가 저감되는 흑도라지의 제조방법 | |
KR101344244B1 (ko) | 냉수용해성 천마 추출물의 제조 방법 및 상기 추출물을 함유하는 항암용 약학 조성물 | |
CN105412613B (zh) | 一种用于老年痴呆症的配方及其加工方法 | |
Bersani‐Amado et al. | Antiulcer effectiveness of Maytenus aquifolium spray dried extract | |
CN108041558A (zh) | 一种养生酱油及其制备方法 | |
KR20100101988A (ko) | 누에 체액 추출물을 포함하는 건강보조식품 및 이의 제조 방법 | |
KR100721931B1 (ko) | 차가버섯을 이용한 당뇨예방용 파우치제품과 그 제조방법 | |
Gupta et al. | Ultrasonication Extraction Techniques for a New Approach for Development of Pharmacognostical and Phytochemical Screening of Syzygium aromaticum | |
JP2007063206A (ja) | 中性脂肪蓄積抑制剤 | |
RU2812611C1 (ru) | Композиции из гинзенозида Rg3 и гинзенозида Rg5 и их фармацевтическое применение, включая противоопухолевые эффекты | |
CN105747215B (zh) | 辅酶q10水分散体及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20191119 |